文献速递淋巴瘤

GAIA/CLL13与CLL2-GIVe试验中接受维奈克拉方案治疗的CLL端粒长度分析

Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.
PubMed 文献 · Blood · 2026-10-06

在GAIA/CLL13试验中,对917例无TP53异常初治CLL患者用qPCR分析端粒长度,比较维奈克拉联合方案与化学免疫治疗;CLL2-GIVe中分析41例TP53异常初治患者接受GIV。短端粒与不良临床及遗传特征相关,并在各治疗组中与更短PFS相关,仅在CIT组影响OS。

要点

  • GAIA/CLL13中端粒长度预后截断值为4.17 kb,据此分为短端粒与长端粒。
  • 短端粒与晚期Binet分期、高ECOG、高β2微球蛋白及高胸苷激酶等不良特征相关。
  • 短端粒在CIT、RV、GV、GIV各组均与更短PFS相关,仅在CIT组影响OS。

核心结论

  • 端粒长度可能作为接受维奈克拉为基础一线治疗的CLL患者PFS的预后标志物。
  • 端粒长度可能有助于现代治疗时代的风险分层。

研究设计与样本

  • GAIA/CLL13试验纳入917例无TP53异常的初治CLL患者样本,用qPCR分析端粒长度,比较维奈克拉联合方案与化学免疫治疗。
  • CLL2-GIVe试验纳入41例TP53异常的初治CLL患者样本,分析接受GIV治疗的端粒长度。

主要发现

  • GAIA/CLL13和CLL2-GIVe的中位端粒长度分别为4.0 kb(1.2-15.2)和2.8 kb(1.4-14.0)。
  • GAIA/CLL13中短端粒与晚期Binet分期、高ECOG、高血清β2微球蛋白、高胸苷激酶、高淋巴细胞计数及大淋巴结显著相关(均P<0.01)。
  • 短端粒与未突变IGHV、del(11q)、NOTCH1、SF3B1、XPO1、RPS15、EGR2、NFKBIE突变及核型复杂性显著相关(均P<0.01)。
  • GAIA/CLL13中短端粒在CIT、RV、GV、GIV各组均与更短PFS相关(均P<0.01),CLL2-GIVe中按中位数二分后亦相关(P=0.04)。
  • 短端粒仅在CIT组影响总生存(P=0.024);多变量分析提示端粒长度是GAIA/CLL13总体队列PFS的独立预后因素。

关键数值与推荐

  • 基于GAIA/CLL13的预后截断值为4.17 kb,用于将端粒长度二分为短和长。
  • CLL2-GIVe中按中位数二分端粒长度进行PFS分析(P=0.04)。

临床怎么用

  • 对接受维奈克拉为基础一线治疗的CLL患者,可考虑检测端粒长度以辅助PFS风险分层。
  • 短端粒提示不良临床及遗传特征,需加强病情监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Telomere length is a prognostic factor in chronic lymphocytic leukemia (CLL), yet its relevance under targeted therapies remains unclear. Here, we analyzed telomere length using qPCR in 917 samples from treatment-naïve CLL patients without TP53 aberrations enrolled in the GAIA/CLL13 trial comparing venetoclax-based combinations with rituximab (RV), obinutuzumab (GV), or obinutuzumab plus ibrutinib (GIV) versus chemoimmunotherapy (CIT). For CLL with TP53 aberrations, samples from 41 treatment-naïve patients receiving GIV in the CLL2-GIVe trial were analyzed. The median telomere lengths in GAIA/CLL13 and CLL2-GIVe were 4.0 kb (1.2-15.2) and 2.8 kb (1.4-14.0), respectively. A prognostic cutoff of 4.17 kb, based on GAIA/CLL13, was used for dichotomization into short and long telomeres. Within GAIA/CLL13, short telomeres significantly correlated with adverse clinical features including advanced Binet stage, high ECOG, high serum ß2-microglobulin and thymidine kinase levels, high lymphocyte count and large lymph nodes (all P<0.01). Among genetic features, short telomeres significantly associated with unmutated IGHV, del(11q), mutations in NOTCH1, SF3B1, XPO1, RPS15, EGR2 and NFKBIE, and karyotypic complexity (all P<0.01). Short telomeres were associated with shorter progression-free survival (PFS) within CIT, RV, GV, GIV in GAIA/CLL13 (all P<0.01) and in CLL2-GIVe (dichotomized by median; P=0.04), and impacted overall survival only in the CIT arm (P=0.024). Multivariable analysis suggested telomere length as an independent prognostic factor for PFS in the overall GAIA/CLL13 cohort. These findings propose telomere length as a prognostic marker for PFS in CLL patients receiving venetoclax-based first-line therapy and could be of relevance for risk stratification in the modern treatment era. NCT02950051.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jebaraj BMC, Tausch E, Yosifov DY, et al. Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials. Blood. 2026. PMID: 42837320. doi:10.1182/blood.2025032302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。